14-day Premium Trial Subscription Try For FreeTry Free
$1.37
+0.0700 (+5.38%)
At Close: May 03, 2024
Forecast Earnings Fundamentals Insider Trading Signals Historical Prices Predictions News Profile

Range Low Price High Price Comment
30 days $1.22 $1.62 Friday, 3rd May 2024 AKBA stock ended at $1.37. This is 5.38% more than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 7.58% from a day low at $1.32 to a day high of $1.42.
90 days $1.22 $2.47
52 weeks $0.780 $2.47

Historical Akebia Therapeutics prices

Date Open High Low Close Volume
Jan 17, 2023 $0.719 $0.740 $0.695 $0.730 944 447
Jan 13, 2023 $0.681 $0.728 $0.680 $0.695 1 031 648
Jan 12, 2023 $0.688 $0.690 $0.650 $0.690 836 400
Jan 11, 2023 $0.650 $0.688 $0.632 $0.670 982 100
Jan 10, 2023 $0.660 $0.660 $0.630 $0.647 690 303
Jan 09, 2023 $0.640 $0.694 $0.633 $0.645 1 340 000
Jan 06, 2023 $0.700 $0.710 $0.622 $0.642 2 133 500
Jan 05, 2023 $0.639 $0.688 $0.626 $0.670 2 319 861
Jan 04, 2023 $0.630 $0.650 $0.580 $0.633 3 399 855
Jan 03, 2023 $0.585 $0.651 $0.550 $0.623 3 899 374
Dec 30, 2022 $0.491 $0.578 $0.490 $0.577 3 566 240
Dec 29, 2022 $0.423 $0.540 $0.423 $0.506 4 686 238
Dec 28, 2022 $0.410 $0.440 $0.409 $0.423 1 216 768
Dec 27, 2022 $0.420 $0.440 $0.412 $0.412 1 369 246
Dec 23, 2022 $0.407 $0.440 $0.407 $0.427 681 203
Dec 22, 2022 $0.406 $0.450 $0.404 $0.411 1 869 794
Dec 21, 2022 $0.412 $0.434 $0.409 $0.411 862 801
Dec 20, 2022 $0.399 $0.446 $0.384 $0.420 1 990 372
Dec 19, 2022 $0.455 $0.460 $0.365 $0.400 2 717 908
Dec 16, 2022 $0.440 $0.479 $0.430 $0.442 3 357 121
Dec 15, 2022 $0.450 $0.460 $0.390 $0.454 2 442 383
Dec 14, 2022 $0.428 $0.480 $0.392 $0.453 3 589 417
Dec 13, 2022 $0.395 $0.440 $0.386 $0.424 3 789 975
Dec 12, 2022 $0.308 $0.408 $0.308 $0.373 3 834 057
Dec 09, 2022 $0.298 $0.318 $0.298 $0.310 689 721
Click to get the best stock tips daily for free!

About Akebia Therapeutics

Akebia Therapeutics Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citra... AKBA Profile

Golden Star

Ticker Date Change Price
CVBF May 01 2.75% $16.75
FTSL May 01 0.282% $46.03
EQC Apr 30 0.694% $18.72
HRB Apr 30 0.635% $47.23
BSCQ Apr 30 0.576% $19.09
BSJP Apr 29 0.306% $22.91
LYG Apr 29 1.56% $2.56
ORA Apr 29 4.68% $64.48
DHT Apr 24 3.10% $11.28
LPLA Apr 19 3.12% $262.59
Unlock

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT